[
  {
    "ts": null,
    "headline": "Allspring Ultra Short-Term Income Fund Q3 2024 Commentary",
    "summary": "The Allspring Ultra Short-Term Income Fund outperformed its benchmark Index for the third quarter of 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=61ac48e5207e2aaf2cae3bde722678de4c4eeedea74834c53ba41b7ac44279d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734035400,
      "headline": "Allspring Ultra Short-Term Income Fund Q3 2024 Commentary",
      "id": 131956080,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1464312021/image_1464312021.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Allspring Ultra Short-Term Income Fund outperformed its benchmark Index for the third quarter of 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=61ac48e5207e2aaf2cae3bde722678de4c4eeedea74834c53ba41b7ac44279d5"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts?",
    "summary": "We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best safe stocks to buy according to analysts. Market Will End 2024 Positively, Strategist Says Statistically, November and December tend to be […]",
    "url": "https://finnhub.io/api/news?id=73bbc4f1b349eecbb8813dff49d59ddf8296f154bf2bd029a54aac365bdd9afe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734007316,
      "headline": "Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts?",
      "id": 131933032,
      "image": "https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best safe stocks to buy according to analysts. Market Will End 2024 Positively, Strategist Says Statistically, November and December tend to be […]",
      "url": "https://finnhub.io/api/news?id=73bbc4f1b349eecbb8813dff49d59ddf8296f154bf2bd029a54aac365bdd9afe"
    }
  },
  {
    "ts": null,
    "headline": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
    "summary": "AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield.  Here's what makes AbbVie a long-term buy-and-hold dividend gold mine.  Why did AbbVie's stock dip?",
    "url": "https://finnhub.io/api/news?id=5c64ca2bd8b3efaf20361d5a1826f1e8d24c4ea53c0e781749f42707d5399950",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734001200,
      "headline": "1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever",
      "id": 131933035,
      "image": "https://g.foolcdn.com/editorial/images/800276/person-working-in-pharmacy.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield.  Here's what makes AbbVie a long-term buy-and-hold dividend gold mine.  Why did AbbVie's stock dip?",
      "url": "https://finnhub.io/api/news?id=5c64ca2bd8b3efaf20361d5a1826f1e8d24c4ea53c0e781749f42707d5399950"
    }
  },
  {
    "ts": null,
    "headline": "Vraylar sales growth seen slowing in 2025, says Richter CEO",
    "summary": "Hungarian pharmaceutical company Richter expects a slowdown in sales growth for its flagship product, Vraylar, next year while supply chain disruptions continue to pose challenges, CEO Gabor Orban...",
    "url": "https://finnhub.io/api/news?id=03691a6241e074836d99eadca7136977a8d800920ee09330e4500f3541f519df",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733993394,
      "headline": "Vraylar sales growth seen slowing in 2025, says Richter CEO",
      "id": 131928361,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Hungarian pharmaceutical company Richter expects a slowdown in sales growth for its flagship product, Vraylar, next year while supply chain disruptions continue to pose challenges, CEO Gabor Orban...",
      "url": "https://finnhub.io/api/news?id=03691a6241e074836d99eadca7136977a8d800920ee09330e4500f3541f519df"
    }
  }
]